Molecular Genetics & Genomic Medicine, published by WILEY, is an esteemed and open-access journal that has been a prominent source of knowledge in the fields of genetics and molecular biology since its establishment in 2013. With an ISSN of 2324-9269, it aims to provide a platform for the dissemination of novel findings and innovative research that pushes the boundaries of genomics and its clinical applications. The journal holds a Q3 categorization in Genetics, Clinical Genetics, and Molecular Biology, reflecting its growing influence in these disciplines, as evidenced by its Scopus rankings. Researchers, professionals, and students alike will find valuable insights and advancements in genomic medicine, making this journal an essential resource for those dedicated to the understanding and application of genetic and molecular research in healthcare. Located at 111 River St, Hoboken, NJ, Molecular Genetics & Genomic Medicine continues to foster a global dialogue within the scientific community, ensuring accessible knowledge for all.

CYTOGENETIC AND GENOME RESEARCH is a pivotal journal dedicated to the exploration of cytogenetics, genomics, and their applications within clinical genetics and molecular biology. Published by KARGER in Switzerland, this journal aims to foster comprehensive discussions and disseminate impactful research from diverse fields related to genetics. It operates under an open access model, ensuring that researchers, professionals, and students can easily access and contribute to the latest findings. With coverage spanning from 1962 to 2024, CYTOGENETIC AND GENOME RESEARCH continues to serve as a vital resource, despite its current categorization in the Q4 quartile across Genetics and Molecular Biology. It provides an avenue for advancing the understanding of genomic mechanisms and their implications for human health. The journal encourages submissions that delve into cutting-edge methodologies, data interpretation, and theoretical frameworks, thereby playing a crucial role in the advancement of genetic research and its clinical applications.

Fetal and Pediatric Pathology, an esteemed journal published by TAYLOR & FRANCIS INC, is dedicated to advancing the field of pediatric and fetal medicine through the dissemination of high-quality research and clinical insights. With an ISSN of 1551-3815 and an E-ISSN of 1551-3823, the journal has been a key resource for researchers and practitioners since its inception in 1983. Based in the United Kingdom, it covers a broad spectrum of topics relevant to Medicine, Pathology and Forensic Medicine, and Pediatrics, Perinatology, and Child Health, consistently reflecting on contemporary challenges faced in these fields. The journal has attained a commendable Q3 ranking within its categories as of 2023, underlining its relevance in the academic community. Though not an open-access publication, the research presented in Fetal and Pediatric Pathology plays a pivotal role in informing practice, guiding future studies, and enhancing the understanding of diseases affecting fetuses and children. Its convergence of research throughout multiple years, continuing until 2024, marks it as a crucial platform for ongoing scientific dialogue and innovation, aimed at fostering better health outcomes for younger populations.

Reproductive Medicine is an esteemed open-access journal published by MDPI, focusing on the latest research and advances in reproductive health, fertility, and assisted reproductive technologies. With its E-ISSN of 2673-3897, the journal aims to provide a platform for researchers, clinicians, and healthcare professionals to disseminate their findings, share innovative practices, and engage in scholarly discourse. Situated in Basel, Switzerland, Reproductive Medicine emphasizes a multidisciplinary approach, exploring biological, clinical, and psychological aspects of reproductive health. Although the journal is in the early stages of establishing metrics such as H-index and Scopus rankings, its open-access model enhances accessibility, allowing for a broad dissemination of knowledge. Committed to fostering advancements in the field, Reproductive Medicine is essential for those seeking to stay at the forefront of reproductive health research.

CHROMOSOMA is a prestigious journal dedicated to advancing the field of genetics, published by Springer in Germany. With an ISSN of 0009-5915 and an E-ISSN of 1432-0886, this journal has been a cornerstone in the publishing landscape since its inception in 1939, serving as a critical resource for researchers and professionals interested in the intricacies of chromosomal biology. Although it operates on a subscription basis, the journal's rigorous peer-review process ensures the dissemination of high-quality research findings. With a commendable Q2 ranking in both genetic and clinical genetics categories as of 2023, CHROMOSOMA aims to bridge theoretical concepts with practical applications in medicine and biology. Researchers will appreciate its relevance, as indicated by its Scopus ranks and integration of diverse topics ranging from molecular genetics to clinical implications. By fostering collaboration and knowledge-sharing among scholars, CHROMOSOMA continues to shape the future of genetic research.

Leukemia Research is a prominent academic journal dedicated to advancing the field of hematology and oncology, focusing on the latest research developments related to leukemia and other hematological disorders. Founded in 1977 and published by Pergamon-Elsevier Science Ltd in the United Kingdom, this esteemed journal has established itself as a vital resource for researchers and clinicians alike. With an impressive impact factor and categorized in the top quartiles of Cancer Research and Hematology, it provides a platform for high-quality research articles, reviews, and clinical studies that contribute to a deeper understanding of leukemia's complexities. Although not an Open Access journal, Leukemia Research ensures widespread dissemination of knowledge crucial for developing innovative treatment strategies and improving patient outcomes. Researchers, professionals, and students in the fields of hematology and oncology will find this journal an invaluable asset in staying at the forefront of leukemia research, as it prepares to expand its impact through converged years of publication extending into 2024.

Molecular Syndromology is a premier journal focused on the intricate connections between molecular genetics and syndromology, fostering discussions that advance our understanding of genetic disorders and their clinical implications. Published by KARGER, a distinguished name in medical and scientific publishing, this journal serves as a valuable platform for researchers, clinicians, and students in the field of genetics. With its ISSN 1661-8769 and E-ISSN 1661-8777, the journal has gained recognition in its category, currently positioned in the Q4 quartile for both genetic and clinical genetics disciplines according to the latest metrics. Despite being indexed lower in Scopus rankings, it addresses crucial gaps in research and offers open access options that enhance visibility and dissemination of knowledge. As it continues to converge from 2010 to 2024, Molecular Syndromology aims to bridge the gap between molecular research and its clinical applications, making a significant impact in the evolving landscape of genetic medicine.

Comparative Cytogenetics, an esteemed journal published by PENSOFT PUBLISHERS, is a pivotal resource in the fields of animal science, biotechnology, genetics, insect science, and plant science. Since its inception as an Open Access journal in 2009, it has significantly contributed to the democratization of scientific knowledge, allowing researchers and students across the globe to access cutting-edge developments in cytogenetics. With an impressive range of articles published from 2010 to 2024, this journal has achieved a commendable impact within the academic community, earning a Q3 ranking in Animal Science and Zoology, Biotechnology, and Insect Science, as well as a Q4 ranking in Genetics, indicating its growing influence. Its Scopus rankings reflect a solid standing, with notable percentiles showcasing its relevance across diverse biological sciences. Located in Sofia, Bulgaria, Comparative Cytogenetics serves not only to disseminate research but also to foster collaboration in understanding cytogenetic dynamics, making it an essential platform for professionals, researchers, and students alike.

NUCLEUS-INDIA is a prominent academic journal that delves into the intricate realms of Cell Biology, Genetics, Molecular Biology, and Molecular Medicine. Published by SPRINGER INDIA, this journal has been a reliable source of innovative research since its inception in 2011. With an ISSN of 0029-568X and an E-ISSN of 0976-7975, NUCLEUS-INDIA stands out in the scientific community, functioning as a critical platform for the dissemination of groundbreaking findings and advancements within its fields of study. Despite being categorized in the lower quartiles as of 2023, it remains an important contributor to the literature, providing insights that influence both academic and practical perspectives in genetics and molecular sciences. Researchers, professionals, and students alike can benefit from its diverse array of articles addressing contemporary challenges and innovations. The journal is located at 7th Floor, Vijaya Building, 17, Barakhamba Road, New Delhi 110 001, India, and aims to enhance the scholarly discourse in biology by publishing works that push the boundaries of current understanding.

LEUKEMIA, published by SpringerNature, is a premier journal in the field of hematology and oncology, with ISSN 0887-6924 and E-ISSN 1476-5551. Established in 1987, this esteemed publication serves as a critical platform for disseminating groundbreaking research and comprehensive reviews on the pathophysiology, diagnosis, and treatment of leukemia and related hematological disorders. With a distinguished impact, it holds a top-tier status in several categories, including Q1 rankings in Anesthesiology and Pain Medicine, Cancer Research, Hematology, and Oncology for 2023. The journal is globally recognized for its rigorous peer-review process and is highly regarded among academia, evidenced by its impressive Scopus rankings—7th in Hematology and 24th in Oncology. Researchers, clinicians, and students alike will benefit from the rich content that this journal offers, making it an invaluable resource in the fight against leukemia. The main objective of LEUKEMIA is to advance knowledge and encourage further innovations within the field, ensuring that vital insights reach practitioners and researchers around the world.